Budget impact of sequential treatment with first-line afatinib versus first-line osimertinib in non-small-cell lung cancer patients with common EGFR mutations

BACKGROUND: The therapeutic landscape for non-small-cell lung cancer (NSCLC) patients that have common epidermal growth factor receptor (EGFR) mutations has changed radically in the last decade. The availability of these treatment options has an economic impact, therefore a budget impact analysis wa...

Descripción completa

Detalles Bibliográficos
Autores principales: Westerink, Lotte, Nicolai, Jelmer L. J., Samuelsen, Carl, Smit, Hans J. M., Postmus, Pieter E., Griebsch, Ingolf, Postma, Maarten J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2020
Materias:
Original Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7366569/
https://www.ncbi.nlm.nih.gov/pubmed/32328874
http://dx.doi.org/10.1007/s10198-020-01186-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7366569/
https://www.ncbi.nlm.nih.gov/pubmed/32328874
http://dx.doi.org/10.1007/s10198-020-01186-9

Ejemplares similares